Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Abstract: The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.

Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: With a portal server, a request for information from a terminal of a second user that is an agent for a first user is received, and an encrypted data directed to a terminal of the first user, stored in an encrypted-data memory unit, is re-encrypted using a re-encryption key for the second user, stored in a first encryption-key memory unit, and is transmitted to the terminal of the second user, with the terminal of the second user, the re-encrypted data received is decrypted using an encryption key for the second user, stored in a second encryption-key memory unit, and time keys specified by the terminal of the first user, related to a time-period during which browsing of the information is permitted.

Abstract: A data authenticity assurance method carried out by a management computer including: a first step of receiving the first data piece from the computer; a second step of selecting a plurality of second data pieces at predetermined intervals in chronological order from among the plurality of second data pieces held in the data holding part; a third step of performing an arithmetic operation for each of the hash values of the selected plurality of second data pieces; a fourth step of generating signature target data by combining the first data piece received from the computer with the hash values of the selected plurality of second data pieces; and a fifth step of generating a second data piece by assigning the digital signature to the signature target data by using the preset key, and holding the generated second data piece in chronological order sequentially in the data holding part.

Abstract: With a portal server, a request for information from a terminal of a second user that is an agent for a first user is received, and an encrypted data directed to a terminal of the first user, stored in an encrypted-data memory unit, is re-encrypted using a re-encryption key for the second user, stored in a first encryption-key memory unit, arid is transmitted to the terminal of the second user, with the terminal of the second user, the re-encrypted data received is decrypted using an encryption key for the second user, stored in a second encryption-key memory unit, and time keys specified by the terminal of the first user, related to a time-period during which browsing of the information is permitted.

Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

Abstract: A data authenticity assurance method carried out by a management computer including: a first step of receiving the first data piece from the computer; a second step of selecting a plurality of second data pieces at predetermined intervals in chronological order from among the plurality of second data pieces held in the data holding part; a third step of performing an arithmetic operation for each of the hash values of the selected plurality of second data pieces; a fourth step of generating signature target data by combining the first data piece received from the computer with the hash values of the selected plurality of second data pieces; and a fifth step of generating a second data piece by assigning the digital signature to the signature target data by using the preset key, and holding the generated second data piece in chronological order sequentially in the data holding part.

Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

Abstract: The present invention shortens the time required for watch list verification, and shortens the time required generally for the personal identification processing which includes watch list verification. In a personal identification system, a biometric information watch list comparison function (31) performs a first comparison of first biometric information in a traveler information DB (53), and biometric information on a biometric information watch list (52). Thereafter, a simplified alien immigration examination comparison function (41) performs a second comparison of the first biometric information in the traveler information DB (53), and second biometric information acquired by a biometric information acquisition function (62). As a result of the comparison, in the case where the difference between the time of the first comparison and the current time is within a previously defined time period, a terminal displays a first comparison result, and a second comparison result.

Abstract: The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.

Abstract: In additional enrollment of a template in a biometric authentication system, the template is automatically enrolled on the basis of a plurality of authentication results to assure a user's convenience and security. A post-migration authentication server receives a first template and a second template from a post-migration authentication terminal, performs authentication on the basis of the comparison result between the received first template and the user's preliminarily first enrolled template, and provisionally enrolls the first template and the second template. It repeats the reception, authentication, and provisional enrollment and calculates a match probability from a plurality of comparison results of the provisionally first enrolled templates, determines whether or not to store a second enrolled template on the basis of the match probability, and automatically enrolls the second template in the post-migration authentication server.

Abstract: In a biometric authentication system, a delivery server includes a parameter conversion unit which generates, by converting the parameter, a parameter for delivery, a template conversion unit which generates, by converting the template, a template for delivery, and a delivery unit which delivers the template for delivery and the parameter for delivery to one of the client terminal and an authentication device; the authentication device includes a sensor which obtains biometric information on a registered user, a feature quantity obtaining unit which obtains a feature quantity from the biometric information, and a feature quantity conversion unit which generates, by converting the feature quantity using the parameter for delivery, a converted feature quantity; and the client terminal includes a match determination unit which determines, by comparing the converted feature quantity with the template for delivery, whether or not the converted feature quantity and the template for delivery match.

Abstract: At registration time, feature data array for registration is generated from biometric information, and position correction template and comparison template. At authentication time, feature data array for authentication is generated from biometric information acquired by the client, and converted feature data for position correction obtained by converting the feature data array for authentication is transmitted to the server. The server detects position correction amount of the feature data array for authentication relative to the feature data array for registration using the position correction template and the converted feature data, and transmits the position correction amount to client. Client corrects the feature data array for authentication and transmits the converted feature data array for comparison to the server.

Abstract: The present invention provides a system and a method for speeding up immigration. In first immigration, first biometric information is stored in a immigration biometric information DB. A normal immigration client terminal displays a first result of comparing an ID information watch list with a biometric information watch list. In subsequent second immigration, the first biometric information in the immigration biometric information DB is compared with second biometric information obtained by a simplified immigration client terminal. Then, the simplified immigration client terminal displays a second result of comparing the first biometric information with the watch list information that is added after the first comparison is done. Thus even if the number of registrations in a watch list database is large, a small amount of similar watch list information is displayed, reducing the time for checking the results by the operator.